Cerebral vasodilators (second of two parts).
D000368:Aged; D000818:Animals; D001621:Betahistine / Q000494:pharmacology / Q000627:therapeutic use; D002560:Cerebrovascular Circulation / Q000187:drug effects; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D002936:Cinnarizine / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003704:Dementia / Q000188:drug therapy*; D004088:Dihydroergotoxine / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007556:Isoxsuprine / Q000494:pharmacology / Q000627:therapeutic use; D009539:Nicotinic Acids / Q000494:pharmacology / Q000627:therapeutic use; D009756:Nylidrin / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D011941:Receptors, Adrenergic / Q000187:drug effects; D011968:Receptors, Histamine / Q000187:drug effects; D014665:Vasodilator Agents / Q000627:therapeutic use*; D014749:Vincamine / Q000494:pharmacology / Q000627:therapeutic use
D009539:Nicotinic Acids; D011941:Receptors, Adrenergic; D011968:Receptors, Histamine; D014665:Vasodilator Agents; D004088:Dihydroergotoxine; D002936:Cinnarizine; D009756:Nylidrin; D014749:Vincamine; D007556:Isoxsuprine; D001621:Betahistine